Bellevue Advisors LLP
Investment
2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and BB Biotech's holdings in focus. The investment team expects new product launches...
Sponsored
26 February 2018
•
3 min read
26 February 2018
•
3 min read
Most read
01
Just Eat Takeaway to delist from London Stock Exchange
27 November 2024
•
1 min read
02
Jupiter's Jason Pidcock on ESG 'nonsense' and why China remains 'unappealing'
27 November 2024
•
5 min read
03
FCA unveils consultation into repealing MiFID organisational requirements
27 November 2024
•
2 min read
04
Investors divided over impact of Trump's tariffs
27 November 2024
•
4 min read
05
Unicorn AIM VCT eyes £20m subscription offer
27 November 2024
•
1 min read
